Kidney/Renal Cancer

Show Only Open Trials
2.

A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

  • Study Status: Open to Enrollment
  • Sponsor: Bristol-Myers Squibb
  • Disease Status and/or Stage: Advanced or Metastatic Kidney Cancer
  • Protocol ID: BMS CA209-025-041
4.

A Phase I/II Study of Vorinostat in Combination with Isotretinoin in the Treatment of Patients with Advanced Renal Cell Carcinoma

  • Study Status: Closed to Enrollment
  • Sponsor: Weill Cornell Medical College, National Cancer Institute
  • Disease Status and/or Stage: Metastatic or Advanced Kidney Cancer
5.

A Phase I/II Trial of BAY 43-9006 plus Gemcitabine and Capecitabine in the Treatment of Patients with Advanced Renal Cell Carcinoma

  • Study Status: Closed to Enrollment
  • Sponsor: Weill Cornell Medical College, National Cancer Institute
  • Disease Status and/or Stage: Advanced, Unresectable and/or Metastatic Kidney Cancer
6.

ECOG 2805: A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (RCC)

  • Study Status: Closed to Enrollment
  • Sponsor: Eastern Cooperative Oncology Group
  • Disease Status and/or Stage: Renal Cell Cancer
7.

A Phase I Study of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-591) in Patients with Nonprostate Metastatic Solid Tumors: A Pilot Study

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Metastatic Solid Tumor

Top of page